Kristina Drizyte-Miller, Taiwo Talabi, Ashwin Somasundaram, Adrienne D. Cox, Channing J. Der
8 min
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with a survival landscape dominated by four primary genetic drivers: KRAS, CDKN2A, TP53, and SMAD4. Among these, the KRAS oncogene is the central culprit, present in approximately 95% of cases. Research confirms that KRAS mutation is the initiating step for pancreatic neoplasia and, crucially, is required for the maintenance of established tumors. Despite this clear dependence, PDAC has historically remained resistant to targeted therapy, forcing patients to rely on highly toxic, traditional cytotoxic chemotherapy cocktails.
For nearly 40 years, KRAS was considered undruggable due to its high affinity for GTP and a lack of traditional binding pockets. This changed with the discovery of the switch II pocket, which allowed for the development of covalent inhibitors targeting specific mutations like KRASG12C. While these inhibitors achieved success in lung and colorectal cancers, they represent only a tiny fraction of the PDAC patient population. Current research has shifted toward more sophisticated approaches, including allele-specific inhibitors for the prevalent G12D mutation and pan-RAS inhibitors that target multiple mutant isoforms alongside wild-type RAS. The latter, including agents like daraxonrasib, represent a major shift, as they bypass the selectivity limitations that previously hindered drug development.
Directly inhibiting KRAS is only the beginning. Clinical data shows that PDAC employs a highly adaptive resistance strategy. When a single pathway is blocked, the tumor often reactivates downstream signaling through alternative RTKs, bypass mutations, or transcriptional reprogramming. Consequently, current clinical strategy is pivoting toward combinatorial therapies—pairing KRAS inhibitors with EGFR inhibitors, immune checkpoint blockades, or metabolic modulators to prevent relapse. While these approaches show early promise in maintaining therapeutic efficacy, long-term success will require a deeper understanding of the tumor's non-genetic adaptive responses.
The genetic landscape of pancreatic ductal adenocarcinoma (PDAC) is well-established and dominated by four key genetic driver mutations. Mutational activation of the KRAS oncogene is the initiating genetic event, followed by genetic loss of function of the CDKN2A, TP53, and SMAD4 tumor suppressor genes. Disappointingly, this information has not been leveraged to develop clinically effective targeted therapies for PDAC treatment, where current standards of care remain cocktails of conventional cytotoxic drugs. Nearly all (~95%) PDAC harbors KRAS mutations, and experimental studies have validated the essential role of KRAS mutation in PDAC tumorigenic and metastatic growth. Identified in 1982 as the first gene shown to be aberrantly activated in human cancer, KRAS has been the focus of intensive drug discovery efforts. Widely considered "undruggable," KRAS has been the elephant in the room for PDAC treatment. This perception was shattered recently with the approval of two KRAS inhibitors for the treatment of KRASG12C-mutant lung and colorectal cancer, fueling hope that KRAS inhibitors will lead to a breakthrough in PDAC therapy. In this Review, we summarize the key role of aberrant KRAS signaling in the biology of pancreatic cancer; provide an overview of past, current, and emerging anti-KRAS treatment strategies; and discuss current challenges that limit the clinical efficacy of directly targeting KRAS for pancreatic cancer treatment.
Alex: KRAS binds tightly to its natural molecular partner, GTP, which puts the switch into its active state. Early efforts to compete with that binding failed. Researchers also lacked a suitable pocket where a drug could attach.
Sam: The review also covers indirect approaches. What does their failure teach us about targeting this switch?
Alex: One strategy blocked the addition of a lipid tag that helps KRAS attach to cell membranes. But KRAS could acquire an alternative tag and keep functioning. Initial work had emphasized a related protein that lacked this escape route.
Sam: So treating related proteins as interchangeable concealed a practical resistance mechanism. Did blocking the signals downstream work better?
Alex: Not enough clinically. The review emphasizes a signaling chain called RAF, MEK, and ERK, which relays growth signals from KRAS. Inhibiting that chain ran into toxicity, resistance, and feedback changes that restored signaling.
Sam: That sets up the change in strategy. What made direct targeting possible?
Alex: Researchers discovered a previously unseen pocket that a small molecule could stabilize. It enabled drugs that attach to a particular mutant form, called G12C. That overturned the blanket claim that KRAS could not be drugged.
Sam: But those first approvals were outside pancreatic cancer. How much of the pancreatic disease do they actually cover?
Alex: G12C occurs in less than two percent of pancreatic ductal adenocarcinomas. The approved drugs produced responses in that subgroup, but the review says they did not outperform current standard care. Their treatment-related adverse events were lower than with chemotherapy.
Sam: So proving the target druggable and reaching most pancreatic cancers are separate achievements. Which mutation matters most here?
Alex: G12D accounts for about 41 percent of KRAS mutations in this disease. That makes drugs against it particularly relevant. But the review offers a caution: a promising selective inhibitor, MRTX1133, produced tumor regressions in preclinical models, then failed to advance clinically because drug exposure varied too much.
Sam: That is a useful break in the story: strong activity in models did not guarantee a workable medicine. Are other approaches avoiding that problem?
Alex: Other selective drugs remain in early testing, with encouraging initial results. There are also broader inhibitors covering several mutations, or multiple members of the RAS protein family. Those strategies could reach beyond any single mutation.
Sam: Broader coverage could also affect healthy cells. Does the review see that trade-off in patients?
Alex: It says broad RAS inhibition was expected to be toxic, based on genetic studies. Yet early clinical experience with daraxonrasib was encouraging and generally tolerable. This drug engages active RAS through a three-part complex involving a helper protein, preventing growth-signal transmission.
Sam: What is the strongest pancreatic cancer result they report for that drug, and how much confidence should we put in it?
Alex: The preliminary report covered forty-two patients with pancreatic cancer carrying mutations at the common G12 position. That is a limited cohort, in my judgment, for deciding whether treatment should change.
Sam: What happened in that group?
Alex: The objective response rate was 27 percent, meaning tumors met criteria for measurable shrinkage. This is evidence of antitumor activity, not by itself evidence of longer survival.
Sam: And did they report how long the disease stayed under control?
Alex: Median progression-free survival was eight and a half months: time before worsening or death. The review describes a randomized comparison against second-line chemotherapy as still recruiting. So these preliminary results do not establish superiority over chemotherapy.
Sam: We have a credible target and clinical activity, but not yet the decisive comparison. What most threatens the durability of those responses?
Alex: Resistance, and it is not one escape route. Relapsed tumors can acquire changes in KRAS itself, in signals upstream, or in downstream machinery. They can also change cellular state without an identified genetic resistance mechanism.
Sam: Does that resistance map come mainly from pancreatic cancer, or are the authors borrowing lessons across cancers?
Alex: Their understanding remains limited and draws heavily on G12C inhibitor experience across lung, colorectal, and pancreatic cancers. That matters when choosing combinations. A successful combination elsewhere is a lead for pancreatic cancer, not proof it will transfer.
Sam: The review describes approved combinations with an upstream receptor blocker in colorectal cancer. So combination treatment has precedent, but the relevant pancreatic combinations still need testing.
Alex: Several are under evaluation, including combinations with chemotherapy and immune therapies. The review also covers KRAS-degrading drugs and vaccines, without presenting them as established solutions. Its conclusion is that no best inhibitor class has yet emerged.
Sam: Who should read the full review, and where should they start?
Alex: Pancreatic cancer researchers, signaling biologists, and researchers designing targeted-therapy trials should read it. Start with “Development of direct KRAS inhibitors,” then read the resistance and combination-strategy section alongside it. Compare mutation coverage, clinical maturity, and escape mechanisms, rather than treating every KRAS drug as equivalent.
Sam: And what should everyone else carry away?
Alex: KRAS is no longer undruggable; durable benefit in pancreatic cancer is still the test. The review supports cautious optimism, not a claim that chemotherapy has already been replaced.
Sam: Thanks for listening.